In order to further understand the clinical significance of MAL2, we selected the top three hub genes (MAL2, CDH1, and TPD52) from the GGI network to analyze their potential roles in drug susceptibility in OC according to the Cancer Therapeutics Response Portal (CTRP). The gene discussed is CDH1; the disease is cancer.